PRESS RELEASE

PRESS RELEASES

Press releases

12^th March 2021

Managing global health epidemics while deriving pandemic lessons

Pandemic learnt lessons to strengthen the healthcare system is of top priority. Investing in skilled workforce and healthcare systems along with essential digital infrastructure and technology.

12^th March 2021

Mucormycosis emerging as a ‘new worry’ among Covid patients

BSV is indigenously developing and manufacturing the formulation of Amphotericin B including Liposomal Amphotericin B and Lipid Complex Amphotericin B – the anti-fungal medications that have been recommended for use in life-threatening fungal infections such as mucormycosis.

9^th March 2021

Mucormycosis emerging as new worry in COVID-19 world.

Bharat Serums & Vaccines (BSV) is the first company in India to get a DCGI approval for anti-fungal medication Liposomal Amphotericin B, used for treating deadly mucormycosis.

28^th February 2021

Have you heard of Rh-negative Incompatibility?

RhD happens due to Rh incompatibility, when mother is Rh negative and baby in her womb is Rhpositive. The mother’s body responds to the Rhpositive blood by producing antibodies.

2^nd February 2021

Budget reaction: Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines

Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines said, “The union budget has given a substantial increase to bolster the healthcare sector in India.

1^st February 2021

Industry opens bag of expectations for Union Budget 2021-22

“The Union budget should address long-standing special incentives and subsidies to encourage indigenous drugs and API production in line with Atmanirbharta.

30^th January 2021

Union Budget 2021: Govt should invest in clinical trials, enable policies to empower pharma sector

“The need of the hour for the industry is the availability and affordability of life-saving drugs for our billion-plus populace.

29^th January 2021

Bharat Serum accepts challenge against COVID

Sanjiv Navangul, MD and CEO of Bharat Serums and Vaccines Ltd., said that Bharat Serum and Vaccines (BSV) is conducting the phase III clinical study of Ulinastatin for ARDS patients.

28^th January 2021

Innovation and collaboration will help Indian pharma leapfrog in the global value chain: Experts

India is starting to go up the ladder, be it in response to the pandemic, treatment options, clinical management of patients or vaccines

22^th January 2021

What does the Healthcare Industry want from the Budget?

Sanjiv Navangul, M.D. & CEO of BSV (Bharat Serums & Vaccines Ltd.) believes the budget is likely to focus on a quick ‘recovery’ from pandemic lessons. He says, “The need of the hour for our industry is the availability and affordability of life-saving drugs for our billion-plus populace.

22^th January 2021

Option of ‘BSV’ on ‘COVID’

BSV has developed biological, biotechnology products as well as medicines to date.

15^th January 2021

Union Budget 2021 expectations – Healthcare

Sanjiv Navangul, M.D. & CEO of BSV (Bharat Serums & Vaccines Ltd.) believes the budget is likely to focus on a quick ‘recovery’ from pandemic lessons.

10^th August 2020

BSV initiates the development of therapeutic equine antibody for treating COVID-19 infection

Bharat Serums and Vaccines Limited (BSV), a leading biopharmaceutical company with presence in India and emerging markets, today announced the initiation of equine polyclonal antibody development for SARS-CoV-2.

9^th July 2020

Three Local Cos Working on Antibody Drugs for COVID

BSV has been a pioneer in the development of blood components and therapeutic antibody products for infectious and non-infectious diseases.

9^th June 2020

Bharat Serums secures nod to test sepsis drug on Covid – 19 patients

Joining the list of drugs repurposed for Covid-19, a sepsis drug from Bharat Serums and Vaccines is getting into Phase III clinical trials.

9^th June 2020

Bharat Serums gets permission to conduct clinical study on Covid-19 patients

Bharat Serums and Vaccines has received the Drug Controller General of India’s approval to undertake late stage Phase III clinical trials in Covid patients showing mild-to-moderate acute respiratory distress symptoms.